Prognostic significance of circulating tumor DNA alterations in advanced renal cell carcinoma from SCRUM-Japan MONSTAR-SCREEN: a nationwide genomic profiling project: Genetics and Genomics

Kato, Taigo; Shiota, Masaki; Nishimoto, Koshiro; Matsubara, Nobuaki; Osawa, Takahiro; Abe, Takashige; Yasumizu, Yota; Tanaka, Nobuyuki; Yamamoto, Yoshiyuki; Ishizuya, Yu; Abutani, Hikaru; Bando, Hideaki; Fujisawa, Takao; Nakamura, Yoshiaki; Oya, Mototsugu; Shinohara, Nobuo; Eto, Masatoshi; Yoshino, Takayuki; Nonomura, Norio

doi:https://doi.org/10.1038/s41416-025-02985-8

Prognostic significance of circulating tumor DNA alterations in advanced renal cell carcinoma from SCRUM-Japan MONSTAR-SCREEN: a nationwide genomic profiling project: Genetics and Genomics

Kato, Taigo; Shiota, Masaki; Nishimoto, Koshiro et al.

British Journal of Cancer, 2025, e2200653

アクセス数:62件（2025-08-14 23:46 集計）

固定URL: https://hdl.handle.net/11094/102248

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
BrJCancer	pdf	なし	1.00 MB	15	2025.07.10

Creative Commons : 表示

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Prognostic significance of circulating tumor DNA alterations in advanced renal cell carcinoma from SCRUM-Japan MONSTAR-SCREEN: a nationwide genomic profiling project: Genetics and Genomics
著者	NRID 1000070648021 1000070648021 researchmap permalink taigokato taigokato Scopus Author ID 55414697500 55414697500 ORCID 0000-0002-8681-1407 0000-0002-8681-1407 著者名 Kato, Taigo
	NRID 1000020635445 1000020635445 著者名 Shiota, Masaki
	NRID 1000000365363 1000000365363 著者名 Nishimoto, Koshiro
	著者名 Matsubara, Nobuaki
	NRID 1000060374443 1000060374443 著者名 Osawa, Takahiro
	NRID 1000010399842 1000010399842 著者名 Abe, Takashige
	NRID 1000040464854 1000040464854 著者名 Yasumizu, Yota
	NRID 1000060445244 1000060445244 著者名 Tanaka, Nobuyuki
	NRID 1000090759557 1000090759557 researchmap permalink yoshi229 yoshi229 ORCID 0000-0002-1271-3521 0000-0002-1271-3521 著者名 Yamamoto, Yoshiyuki
	NRID 1000000783854 1000000783854 researchmap permalink okiishi okiishi 著者名 Ishizuya, Yu
	著者名 Abutani, Hikaru
	NRID 1000000630948 1000000630948 著者名 Bando, Hideaki
	著者名 Fujisawa, Takao
	NRID 1000060776384 1000060776384 著者名 Nakamura, Yoshiaki
	NRID 1000000213885 1000000213885 著者名 Oya, Mototsugu
	NRID 1000090250422 1000090250422 著者名 Shinohara, Nobuo
	NRID 1000090315078 1000090315078 著者名 Eto, Masatoshi
	NRID 1000020469969 1000020469969 著者名 Yoshino, Takayuki
	NRID 1000030263263 1000030263263 researchmap permalink read0185096 read0185096 Scopus Author ID 7005880662 7005880662 著者名 Nonomura, Norio
内容	Kato T., Shiota M., Nishimoto K., et al. Prognostic significance of circulating tumor DNA alterations in advanced renal cell carcinoma from SCRUM-Japan MONSTAR-SCREEN: a nationwide genomic profiling project: Genetics and Genomics. British Journal of Cancer, e2200653 (2025); https://doi.org/10.1038/s41416-025-02985-8.
抄録	Background: Circulating tumor DNA (ctDNA) is a promising tool for diagnosing and predicting cancer prognosis. However, its clinical utility in metastatic renal cell carcinoma (mRCC) remains unclear, particularly in terms of clinical prognosis. Methods: We enrolled 124 patients with mRCC in the MONSTAR-SCREEN study (UMIN 000036749) between August 2019 and February 2022, a national observational ctDNA-based screening study, and performed ctDNA sequencing before and at the time of resistance to systemic therapy. Results: ctDNA were assessed in 178 samples containing 432 mutations. The most frequently altered genes at baseline were VHL (25.0%), PBRM1 (10.9%), TERT2 (8.7%), BAP1 (8.7%), and MTOR (7.6%). Patients receiving first-line therapy with tumor fraction (TF) < 1.2% showed significantly better progression-free survival than those with TF ≥ 1.2% (Hazard ratio (HR) = 0.467; 95% CI 0.229–0.979; p = 0.0425). BAP1 mutational status of ctDNA at baseline led to poor OS (HR = 0.4867; 95% CI 0.322–0.736; p = 0.0003). Serial ctDNA analysis showed that 46.8% of patients developed new ctDNA mutations at disease progression, which was linked to shorter time to progression (p = 0.046). Conclusions: Our findings demonstrated that ctDNA profiling is feasible in mRCC and can predict disease progression after treatment.
出版者	Springer Nature
収録物名	British Journal of Cancer
ページ	e2200653
刊行年月	2025-05-05
言語	英語
ハンドルURL	https://hdl.handle.net/11094/102248
PISSN	00070920
eISSN	15321827
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.1038/s41416-025-02985-8
アクセス権	open access
権利情報	This article is licensed under a Creative Commons Attribution 4.0 International License.
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCMI資源タイプ	text
DCTERMS.bibliographicCitation	British Journal of Cancer. 2025, p. e2200653
DC.title	Prognostic significance of circulating tumor DNA alterations in advanced renal cell carcinoma from SCRUM-Japan MONSTAR-SCREEN: a nationwide genomic profiling project: Genetics and Genomics
DC.creator	Kato, Taigo
	Shiota, Masaki
	Nishimoto, Koshiro
	Matsubara, Nobuaki
	Osawa, Takahiro
	Abe, Takashige
	Yasumizu, Yota
	Tanaka, Nobuyuki
	Yamamoto, Yoshiyuki
	Ishizuya, Yu
	Abutani, Hikaru
	Bando, Hideaki
	Fujisawa, Takao
	Nakamura, Yoshiaki
	Oya, Mototsugu
	Shinohara, Nobuo
	Eto, Masatoshi
	Yoshino, Takayuki
	Nonomura, Norio
DC.publisher	Springer Nature
DC.language' scheme='DCTERMS.RFC1766	英語
DC.type' scheme='DCTERMS.DCMIType	text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2025-05-05
DC.identifier	https://doi.org/10.1038/s41416-025-02985-8
DC.description	Kato T., Shiota M., Nishimoto K., et al. Prognostic significance of circulating tumor DNA alterations in advanced renal cell carcinoma from SCRUM-Japan MONSTAR-SCREEN: a nationwide genomic profiling project: Genetics and Genomics. British Journal of Cancer, e2200653 (2025); https://doi.org/10.1038/s41416-025-02985-8.
DCTERMS.abstract	Background: Circulating tumor DNA (ctDNA) is a promising tool for diagnosing and predicting cancer prognosis. However, its clinical utility in metastatic renal cell carcinoma (mRCC) remains unclear, particularly in terms of clinical prognosis. Methods: We enrolled 124 patients with mRCC in the MONSTAR-SCREEN study (UMIN 000036749) between August 2019 and February 2022, a national observational ctDNA-based screening study, and performed ctDNA sequencing before and at the time of resistance to systemic therapy. Results: ctDNA were assessed in 178 samples containing 432 mutations. The most frequently altered genes at baseline were VHL (25.0%), PBRM1 (10.9%), TERT2 (8.7%), BAP1 (8.7%), and MTOR (7.6%). Patients receiving first-line therapy with tumor fraction (TF) < 1.2% showed significantly better progression-free survival than those with TF ≥ 1.2% (Hazard ratio (HR) = 0.467; 95% CI 0.229–0.979; p = 0.0425). BAP1 mutational status of ctDNA at baseline led to poor OS (HR = 0.4867; 95% CI 0.322–0.736; p = 0.0003). Serial ctDNA analysis showed that 46.8% of patients developed new ctDNA mutations at disease progression, which was linked to shorter time to progression (p = 0.046). Conclusions: Our findings demonstrated that ctDNA profiling is feasible in mRCC and can predict disease progression after treatment.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	102248
citation_title	Prognostic significance of circulating tumor DNA alterations in advanced renal cell carcinoma from SCRUM-Japan MONSTAR-SCREEN: a nationwide genomic profiling project: Genetics and Genomics
citation_author	Kato, Taigo
	Shiota, Masaki
	Nishimoto, Koshiro
	Matsubara, Nobuaki
	Osawa, Takahiro
	Abe, Takashige
	Yasumizu, Yota
	Tanaka, Nobuyuki
	Yamamoto, Yoshiyuki
	Ishizuya, Yu
	Abutani, Hikaru
	Bando, Hideaki
	Fujisawa, Takao
	Nakamura, Yoshiaki
	Oya, Mototsugu
	Shinohara, Nobuo
	Eto, Masatoshi
	Yoshino, Takayuki
	Nonomura, Norio
citation_publisher	Springer Nature
citation_language	英語
citation_date	2025-05-05
citation_journal_title	British Journal of Cancer
citation_firstpage	e2200653
citation_doi	https://doi.org/10.1038/s41416-025-02985-8
citation_public_url	https://hdl.handle.net/11094/102248

Prognostic significance of circulating tumor DNA alterations in advanced renal cell carcinoma from SCRUM-Japan MONSTAR-SCREEN: a nationwide genomic profiling project: Genetics and Genomics

閲覧可能ファイル

論文情報

論文詳細を表示